Profile image
Story Views

Last Hour:
Last 24 Hours:

Xencor, Inc. Treatment Pipeline Review H2 2016

Monday, October 10, 2016 6:16
% of readers think this story is Fact. Add your two cents.

(Before It's News)


‘Xencor, Inc. – Product Pipeline Review – 2016’, provides an overview of the Xencor, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Xencor, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Complete report details @

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


- The report provides a snapshot of the pipeline therapeutic landscape of Xencor, Inc. 
- The report provides overview of Xencor, Inc. including its business description, key facts, and locations and subsidiaries 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Xencor, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Xencor, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Request a sample report @

Reasons to buy

- Evaluate Xencor, Inc.’s strategic position with total access to detailed information on its product pipeline 
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Xencor, Inc. 
- Identify potential new clients or partners in the target demographic 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Xencor, Inc.’s pipeline depth and focus of pipeline therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Make an enquiry before buying this Report @

Key points in table of content

Table of Contents 
Table of Contents 2 
List of Tables 5 
List of Figures 5 
Xencor, Inc. Snapshot 6 
Xencor, Inc. Overview 6 
Key Information 6 
Key Facts 6 
Xencor, Inc. – Research and Development Overview 7 
Key Therapeutic Areas 7 
Xencor, Inc. – Pipeline Review 10 
Pipeline Products by Stage of Development 10 
Pipeline Products – Monotherapy 11 
Pipeline Products – Partnered Products 12 
Partnered Products/Combination Treatment Modalities 13 
Pipeline Products – Out-Licensed Products 14 
Out-Licensed Products/Combination Treatment Modalities 15 
Xencor, Inc. – Pipeline Products Glance 16 
Xencor, Inc. – Clinical Stage Pipeline Products 16 
Phase II Products/Combination Treatment Modalities 16 
Phase I Products/Combination Treatment Modalities 17 
Xencor, Inc. – Early Stage Pipeline Products 18 
Preclinical Products/Combination Treatment Modalities 18 
Discovery Products/Combination Treatment Modalities 19 
Xencor, Inc. – Drug Profiles 20 
XmAb-5871 20 
Product Description 20 
Mechanism of Action 20 
R&D Progress 20 
Monoclonal Antibody 1 for Oncology 21 
Product Description 21 
Mechanism of Action 21 
R&D Progress 21 
Monoclonal Antibody 2 for Oncology 22 
Product Description 22 
Mechanism of Action 22 
R&D Progress 22 
XmAb-7195 23 
Product Description 23 
Mechanism of Action 23 
R&D Progress 23 
XENP-1138 24 
Product Description 24 
Mechanism of Action 24 
R&D Progress 24 
XmAb-13676 25 
Product Description 25 
Mechanism of Action 25 
R&D Progress 25 
XmAb-13677 26 
Product Description 26 
Mechanism of Action 26 
R&D Progress 26 
XmAb-14045 28 
Product Description 28 
Mechanism of Action 28 
R&D Progress 28 
XmAb-14484 29 
Product Description 29 
Mechanism of Action 29 
R&D Progress 29 
XmAb-18087 30 
Product Description 30 
Mechanism of Action 30 
R&D Progress 30 
XmAb-19722 31 
Product Description 31 
Mechanism of Action 31 
R&D Progress 31 
XmAb-20717 32 
Product Description 32 
Mechanism of Action 32 
R&D Progress 32 
XmAb-6755 33 
Product Description 33 
Mechanism of Action 33 
R&D Progress 33 
Monoclonal Antibody to Agonize CD32b for Immunology 34 
Product Description 34 
Mechanism of Action 34 
R&D Progress 34 
Monoclonal Antibody to Agonize CD32b for Undisclosed Indication 35 
Product Description 35 
Mechanism of Action 35 
R&D Progress 35 
Xencor, Inc. – Pipeline Analysis 36 
Xencor, Inc. – Pipeline Products by Target 36 
Xencor, Inc. – Pipeline Products by Route of Administration 38 
Xencor, Inc. – Pipeline Products by Molecule Type 39 
Xencor, Inc. – Pipeline Products by Mechanism of Action 40 
Xencor, Inc. – Recent Pipeline Updates 41 
Xencor, Inc. – Dormant Projects 45 
Xencor, Inc. – Locations And Subsidiaries 46 
Head Office 46 
Other Locations & Subsidiaries 46 
Appendix 47 
Methodology 47 
Coverage 47 
Secondary Research 47 
Primary Research 47 
Expert Panel Validation 47 
Contact Us 47 
Disclaimer 48

List of Tables 
Xencor, Inc., Key Information 6 
Xencor, Inc., Key Facts 6 
Xencor, Inc. – Pipeline by Indication, 2016 8 
Xencor, Inc. – Pipeline by Stage of Development, 2016 10 
Xencor, Inc. – Monotherapy Products in Pipeline, 2016 11 
Xencor, Inc. – Partnered Products in Pipeline, 2016 12 
Xencor, Inc. – Partnered Products/ Combination Treatment Modalities, 2016 13 
Xencor, Inc. – Out-Licensed Products in Pipeline, 2016 14 
Xencor, Inc. – Out-Licensed Products/ Combination Treatment Modalities, 2016 15 
Xencor, Inc. – Phase II, 2016 16 
Xencor, Inc. – Phase I, 2016 17 
Xencor, Inc. – Preclinical, 2016 18 
Xencor, Inc. – Discovery, 2016 19 
Xencor, Inc. – Pipeline by Target, 2016 37 
Xencor, Inc. – Pipeline by Route of Administration, 2016 38 
Xencor, Inc. – Pipeline by Molecule Type, 2016 39 
Xencor, Inc. – Pipeline Products by Mechanism of Action, 2016 40 
Xencor, Inc. – Recent Pipeline Updates, 2016 41 
Xencor, Inc. – Dormant Developmental Projects,2016 45 
Xencor, Inc., Other Locations 46

Get this report @

Contact US:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.